BANGKOK, July 13 -- PRNewswire/ AsiaNet Clinical trial demonstrates high potency combined with good tolerability Data from a new study with the HIV protease inhibitor Invirase(R) (saquinavir mesylate) has demonstrated the best HIV RNA response yet seen in a large group of HIV-infected patients given highly active antiretroviral therapy.(1-8) The data announced today at the XV International AIDS Conference inBangkok show that a convenient once daily regimen of boosted Invirase(R) plus 2NRTIs delivers excellent antiviral potency: - 96% of patients achieving HIV RNA levels of